Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Recruiting 6Terminated 5Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 27Breast 26Genitourinary 18Gastrointestinal 11Thoracic 8Sarcoma 5CNS 5Head & Neck 4Tumor-Agnostic 2Other solid neoplasm 2Myeloid 2Other hematologic neoplasm 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Solid Tumors 2

Interventions

pembrolizumab 27Pemetrexed 10Nivolumab 10Cyclophosphamide 10Carboplatin 10atezolizumab 8Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6fludarabine 5Injections 5tislelizumab 4spartalizumab 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4sintilimab 3durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × olaparib × Other solid neoplasm × Clear all
NCT00777582 2026-05-08

Phase I Comparative Bioavailability Study

AstraZeneca

Phase 1 Active not recruiting
197 enrolled
Other solid neoplasm

Solid Tumors

NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
300 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡